Virus-Like Drug Conjugates (VDCs)
Our proprietary technology enables the targeting of ocular cancers using Virus-Like Particles, or VLPs, that selectively target tumor cells and deliver conjugated cytotoxic molecules to create Virus-Like Drug Conjugates, or VDCs.
Choroidal melanoma is a rare, vision- and life-threatening ocular cancer
There are no approved drug therapies for the first line treatment of primary choroidal melanoma, and the long-term prognosis is poor with death occurring in more than 50% of cases. Current standard of care treatment with radiotherapy leaves many patients with profound vision loss, potential disfiguration, and a wide range of comorbidities.
New options for early treatment intervention that arrest tumor growth and preserve vision are urgently needed.
News
Make an impact at Aura
We seek passionate, talented individuals who share our vision of building the world’s preeminent ocular oncology company and fulfilling our mission to improve the lives of our patients.